Candel Therapeutics Inc., trading under NASDAQ: CADL, has released a corporate presentation detailing significant developments in their cancer treatment programs. The company highlights their lead candidate, CAN-2409, as an off-the-shelf pan-solid tumor therapy designed to elicit an individualized anti-cancer immune response. The therapy has shown positive phase 3 results in localized, intermediate-to-high-risk prostate cancer, and positive overall survival data in phase 2a trials for both borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. Candel's pipeline also includes CAN-3110, an oncolytic HSV-1 designed for tumor-specific replication, with proof of concept published in _Nature_ for recurrent high-grade glioma. The company notes upcoming data releases for CAN-3110 in Q4 2025. Candel's financial position includes $92.2 million in cash and equivalents as of March 31, 2025, with an expected runway into Q1 2027. You can access the full presentation through the link below.